DNA damage response biotech launches with £25m funding

pharmafile | September 22, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dna damage response, funding 

Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science investors.

Funding was led by a number of investors including AbbVie Ventures and SV Life Sciences with participation from Merck Ventures.

The biotech was formed from assets out of Cancer Research UK’s technology transfer unit and will use this new investment to focus on the development of a pipeline of DNA damage response (DDR) cancer therapies.

The company is led by CEO Dr Niall Martin, who brings “proven expertise” in DDR drug discovery to the role.

Artios said it is actively building a pipeline of “highly promising” first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, in a statement at the London Stock Exchange.

Matt Fellows

Related Content

Nido Biosciences raises $109m in funding for neurological diseases treatments

US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series …

UK AI firm wins share of £140 million funding for lung cancer detection tech

Artificial intelligence firm has won a share of £140 million in government funding for …


Industry comes together to form the AMR Action Fund, pledging $1bn to fight antimicrobial resistance

Over 20 biopharma firms have come together to launch the AMR Action Fund, an initiative …

Latest content